<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>将其添加为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>武田药品工业株式会社（Takeda Pharmaceutical Co. Ltd.，股票代码：TAK）周二表示，美国马萨诸塞州地区法院的陪审团对该公司在 AMITIZA 或 lubiprostone 反垄断诉讼中作出了不利裁决。</p>
<p>陪审团裁定原告获得约 8.849 亿美元的单项赔偿，涉及与 2014 年专利和解协议相关的索赔，该协议涉及该药物的仿制版本。</p>
<p>该公司表示，批发商类别和个别零售商获得的赔偿在判决生效后根据美国反垄断法将自动三倍赔偿。</p>
<p>最终支付者类别获得的赔偿仍需经过进一步的法院程序，才能作出最终判决。</p>
<p>该公司表示将积极追求审判后的动议和上诉，并补充说在审判过程中存在证据和法律错误。</p>
<p>该诉讼涉及对武田、苏康普药品公司（Sucampo Pharmaceuticals, Inc.）和帕尔制药公司（Par Pharmaceutical, Inc.）之间关于 AMITIZA 仿制版本的 2014 年和解协议的反竞争指控。</p>
<p>该公司表示，该协议允许帕尔在 2021 年 1 月推出授权的仿制产品。</p>
<p>该公司表示，推出日期比相关专利到期的时间早了六年多。</p>
<p>该公司表示正在评估在其 2025 财年合并财务报表中确认的准备金金额，并计划在评估完成后修订并重新提交其 2025 财年财报及其他财务材料。</p>
<p>该公司表示，此事不会影响 2025 财年的核心财务结果，并且预计对 2026 财年的财务预测或管理指导不会产生重大影响，除非根据任何付款的金额和时间可能调整自由现金流。</p>
<p>周一，武田药品在纽约证券交易所的交易中收盘下跌 0.24%，报 16.57 美元，跌幅 0.04 美元。在盘后交易中，股票上涨 0.54%，报 16.66 美元，涨幅 0.09 美元。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

<p>泰克达制药有限公司被判赔偿 8.849 亿美元，因其 AMITIZA 药物相关的反垄断案件。该公司计划对这一裁决提出上诉，并将修订其 2025 财年的财务结果，尽管预计对 2025 财年或 2026 财年的核心财务数据不会产生重大影响。泰克达的股票收盘价为 16.57 美元，略有下跌，但在盘后交易中上涨</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>将其添加为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Takeda Pharmaceutical Co. Ltd. (TAK) said Tuesday a jury in the U.S. District Court for the District of Massachusetts returned a verdict against the company in the AMITIZA or lubiprostone antitrust litigation.</p>
<div class="lb-trans"><p>武田药品工业株式会社（Takeda Pharmaceutical Co. Ltd.，股票代码：TAK）周二表示，美国马萨诸塞州地区法院的陪审团对该公司在 AMITIZA 或 lubiprostone 反垄断诉讼中作出了不利裁决。</p>
</div><p>The jury awarded plaintiffs about $884.9 million in single damages related to claims tied to a 2014 patent settlement agreement involving generic versions of the drug.</p>
<div class="lb-trans"><p>陪审团裁定原告获得约 8.849 亿美元的单项赔偿，涉及与 2014 年专利和解协议相关的索赔，该协议涉及该药物的仿制版本。</p>
</div><p>The company said damages awarded to the wholesaler class and individual retailers are subject to automatic trebling under U.S. antitrust law upon entry of judgment.</p>
<div class="lb-trans"><p>该公司表示，批发商类别和个别零售商获得的赔偿在判决生效后根据美国反垄断法将自动三倍赔偿。</p>
</div><p>The damages awarded to the end payor class remain subject to further court proceedings before final judgment is entered.</p>
<div class="lb-trans"><p>最终支付者类别获得的赔偿仍需经过进一步的法院程序，才能作出最终判决。</p>
</div><p>The company said it will vigorously pursue post-trial motions and an appeal, adding that it believes evidentiary and legal errors were made during the trial.</p>
<div class="lb-trans"><p>该公司表示将积极追求审判后的动议和上诉，并补充说在审判过程中存在证据和法律错误。</p>
</div><p>The litigation relates to allegations that a 2014 settlement agreement between Takeda, Sucampo Pharmaceuticals, Inc., and Par Pharmaceutical, Inc. regarding generic versions of AMITIZA was anticompetitive.</p>
<div class="lb-trans"><p>该诉讼涉及对武田、苏康普药品公司（Sucampo Pharmaceuticals, Inc.）和帕尔制药公司（Par Pharmaceutical, Inc.）之间关于 AMITIZA 仿制版本的 2014 年和解协议的反竞争指控。</p>
</div><p>The company said the agreement allowed Par to launch an authorized generic product in January 2021.</p>
<div class="lb-trans"><p>该公司表示，该协议允许帕尔在 2021 年 1 月推出授权的仿制产品。</p>
</div><p>The company said the launch date was more than six years before relevant patents were set to expire.</p>
<div class="lb-trans"><p>该公司表示，推出日期比相关专利到期的时间早了六年多。</p>
</div><p>The company said it is assessing the amount of a provision to be recognized in its full-year 2025 consolidated financial statements related to the matter and plans to revise and re-file its full-year 2025 earnings report and other financial materials once the assessment is completed.</p>
<div class="lb-trans"><p>该公司表示正在评估在其 2025 财年合并财务报表中确认的准备金金额，并计划在评估完成后修订并重新提交其 2025 财年财报及其他财务材料。</p>
</div><p>The company said the matter will not impact full-year 2025 core financial results and does not expect a material impact on full-year 2026 financial forecast or management guidance, except potentially adjusted free cash flow depending on the amount and timing of any payment.</p>
<div class="lb-trans"><p>该公司表示，此事不会影响 2025 财年的核心财务结果，并且预计对 2026 财年的财务预测或管理指导不会产生重大影响，除非根据任何付款的金额和时间可能调整自由现金流。</p>
</div><p>On Monday, Takeda Pharma closed trading 0.24%, 0.04 cents lesser at $16.57 on the New York Stock Exchange. In the overnight, the stock traded 0.54% higher at $16.66, 0.09 cents.</p>
<div class="lb-trans"><p>周一，武田药品在纽约证券交易所的交易中收盘下跌 0.24%，报 16.57 美元，跌幅 0.04 美元。在盘后交易中，股票上涨 0.54%，报 16.66 美元，涨幅 0.09 美元。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

武田在 AMITIZA 反垄断案件中被判支付 884.9 百万美元；将修订 2025 财年的业绩